Next Article in Journal
Natural Marine and Synthetic Xenobiotics Get on Nematode’s Nerves: Neuro-Stimulating and Neurotoxic Findings in Caenorhabditis elegans
Next Article in Special Issue
λ-Carrageenan Suppresses Tomato Chlorotic Dwarf Viroid (TCDVd) Replication and Symptom Expression in Tomatoes
Previous Article in Journal
Eunicellin-Based Diterpenoids, Hirsutalins S–V, from the Formosan Soft Coral Cladiella hirsuta
Previous Article in Special Issue
Employment of Marine Polysaccharides to Manufacture Functional Biocomposites for Aquaculture Feeding Applications
Article Menu

Export Article

Open AccessReview
Mar. Drugs 2015, 13(5), 2770-2784; doi:10.3390/md13052770

Perspective on the Use of Sulfated Polysaccharides from Marine Organisms as a Source of New Antithrombotic Drugs

1
Connective Tissue Research Laboratory, University Hospital Clementino Fraga Filho, Rio de Janeiro, RJ 21941-590, Brazil
2
Program of Glycobiology, Institute of Medical Biochemistry, Federal University of Rio de Janeiro, Caixa Postal 68041, Rio de Janeiro, RJ 21941-590, Brazil 
Academic Editor: Paola Laurienzo
Received: 26 February 2015 / Revised: 14 April 2015 / Accepted: 17 April 2015 / Published: 6 May 2015
(This article belongs to the Collection Marine Polysaccharides)
View Full-Text   |   Download PDF [1546 KB, uploaded 6 May 2015]   |  

Abstract

Thromboembolic diseases are increasing worldwide and always require anticoagulant therapy. We still need safer and more secure antithrombotic drugs than those presently available. Sulfated polysaccharides from marine organisms may constitute a new source for the development of such drugs. Investigation of these compounds usually attempts to reproduce the therapeutic effects of heparin. However, we may need to follow different routes, focusing particularly in the following aspects: (1) defining precisely the specific structures required for interaction of these sulfated polysaccharides with proteins of the coagulation system; (2) looking for alternative mechanisms of action, distinct from those of heparin; (3) identifying side effects (mostly pro-coagulant action and hypotension rather than bleeding) and preparing derivatives that retain the desired antithrombotic action but are devoid of side effects; (4) considering that sulfated polysaccharides with low anticoagulant action on in vitro assays may display potent effects on animal models of experimental thrombosis; and finally (5) investigating the antithrombotic effect of these sulfated polysaccharides after oral administration or preparing derivatives that may achieve this effect. If these aspects are successfully addressed, sulfated polysaccharides from marine organisms may conquer the frontier of antithrombotic therapy and open new avenues for treatment or prevention of thromboembolic diseases. View Full-Text
Keywords: sulfated fucans; sulfated galactans; anticoagulant drugs; glycosaminoglycan-like polysaccharides; fucosylated chondroitin sulfate; fucoidan; carrageenans sulfated fucans; sulfated galactans; anticoagulant drugs; glycosaminoglycan-like polysaccharides; fucosylated chondroitin sulfate; fucoidan; carrageenans
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Mourão, P.A.S. Perspective on the Use of Sulfated Polysaccharides from Marine Organisms as a Source of New Antithrombotic Drugs. Mar. Drugs 2015, 13, 2770-2784.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top